Vancouver-based Absci to send first drug to clinical trials in what CEO calls a ‘huge milestone’
The company also announced a collaboration with chipmaker AMD to power its advanced de novo AI antibody design models, as well as AI biotechnology company Owkin to co-develop therapeutic candidates ...
We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...
We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...
We came across a bullish thesis on Genmab A/S (GMAB) on Substack by Oliver | MMMT Wealth. In this article, we will summarize ...
Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, ...
New active ingredients such as antibodies are usually tested individually in laboratory animals. Researchers have now developed a technology that can be used to test around 25 antibodies ...
Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci ...
The company posted revenue of $0.7 million for Q4 2024, falling short of the $1.8 million consensus estimate. Adjusted earnings per share came in at -$0.25, $0.03 worse than analysts expected.
We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...
The use of AI in drug discovery and development has been recognised, explored, and implemented throughout the last decade, ...
Another company involved in using AI to repurpose failed drugs – as well as drugs that have already been approved – is ...
American biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results